Skip to content
AnalystLens

Roivant Sciences 8-K Report, Corporate Update (Aug 28, 2026)

Reports
Other Events·Exhibits & Filings
Filing Date
Filed August 28, 2026
Period End
August 28, 2026
Security
ROIV
In the record · 2021–202610-K510-Q168-K82

ROIV filed 5 annual reports (10-K), 16 quarterly reports (10-Q) and 82 current reports (8-K) between 2021 and 2026.

  1. Leadership change8-K · Oct ’21Oct ’21
  2. Leadership change8-K · Nov ’22Nov ’22
  3. Deal closed8-K · Dec ’23Dec ’23
  4. Material agreement8-K · Mar ’26Mar ’26

01—Abstract

Summary

Summary of the 8-K filed August 28, 2026. Cited figures are marked; the original filing is the authoritative source.

Roivant Sciences Ltd. (ROIV) filed this Form 8-K on August 28, 2026 to report that the U.S. Food and Drug Administration approved LISRAYA (brepocitinib) for the treatment of adults with dermatomyositis (DM).

The company posted an investor presentation on its investor relations website, filed as Exhibit 99.1. The filing states a wholesale acquisition cost of $35,000a for a 30-count bottle of 30 mg tablets. According to the presentation, LISRAYA is commercially available immediately upon approval, ahead of prior guidance calling for a launch by the end of September 2026.

The presentation cites Phase 3 VALOR results, in which the 30 mg dose reached a mean Total Improvement Score (TIS) of 46.5 versus 31.2 for placebo at Week 52 (p = 0.0006), and TIS40 response rates of 67.9%b versus 44.3%. The product carries a JAK-class boxed warning covering serious infections, mortality, malignancy, major adverse cardiovascular events and thrombosis. The presentation also describes a limited specialty pharmacy distribution network and expects adoption to build gradually given long-established prescribing patterns in DM.

The presentation states that Priovant, a Roivant subsidiary, holds commercial rights to brepocitinib in the U.S. and Japan, and that Roivant owned 71%c of Priovant as of June 30, 2026, with Pfizer owning 24%. Other pipeline indications for brepocitinib, including non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris, remain investigational.

02—Key points

Key Highlights

  1. FDA approved LISRAYA (brepocitinib) for adults with dermatomyositis, with commercial availability announced on the same day, ahead of prior guidance for a launch by end of September 2026.
  2. Wholesale acquisition cost is $35,000 for a 30-count bottle of 30 mg tablets.
  3. In the Phase 3 VALOR study, the 30 mg dose achieved a mean TIS of 46.5 versus 31.2 for placebo at Week 52 (p = 0.0006).
  4. TIS40 response at Week 52 was 67.9% for the 30 mg dose versus 44.3% for placebo; TIS60 response was 46.1% versus 26.4%.
  5. The label carries a boxed warning for serious infections, mortality, malignancy, major adverse cardiovascular events and thrombosis, consistent with the JAK inhibitor class.
  6. Roivant owned 71% of Priovant as of June 30, 2026, with Pfizer owning 24%; Priovant holds U.S. and Japan commercial rights.
  7. The presentation expects additional pivotal readouts over the next 36 months and lists potential sNDA approvals for non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris.

03—Questions

Frequently Asked Questions

  1. What did the FDA approve?

    The FDA approved LISRAYA (brepocitinib) for the treatment of adults with dermatomyositis. The presentation states that all other indications remain investigational and subject to regulatory approval.

  2. How much does LISRAYA cost?

    The filing states a wholesale acquisition cost of $35,000 for a 30-count bottle of 30 mg tablets. The presentation also notes that eligible patients may pay as little as $0 per month through the My Compass Support program.

  3. What were the key efficacy results?

    In the Phase 3 VALOR study, the 30 mg dose showed a mean Total Improvement Score of 46.5 versus 31.2 for placebo at Week 52, with a p-value of 0.0006. TIS40 response was 67.9% versus 44.3% for placebo, and 54.3% of 30 mg patients achieved a TIS40 response with oral corticosteroids of 2.5 mg/day or less, versus 26.6% for placebo.

  4. What are the main safety concerns?

    LISRAYA carries a JAK-class boxed warning for serious infections, mortality, malignancy, major adverse cardiovascular events and thrombosis. In VALOR, serious infections occurred in 8 patients (10%) on the 30 mg dose versus 1 (1%) on placebo.

  5. Who controls the commercial rights and economics?

    The presentation states that Priovant has commercial rights to brepocitinib in the U.S. and Japan, and that Roivant owned 71% of Priovant as of June 30, 2026, on a basic basis (65% fully diluted). Pfizer owned 24%.

04—Continue

← View all 8-K filings